Goodwin Procter advised BridgeBio Pharma, Inc. on the deal. BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced its exclusive license agreement wit Bristol Myers Squibb to develop and […]
BridgeBio Pharma’s License Agreement with Bristol Myers Squibb
OPKO Health’s Acquisition of ModeX Therapeutics
Goodwin advised ModeX Therapeutics, Inc. on the deal while Greenberg Traurig represented OPKO Health Inc. ModeX Therapeutics, Inc. announced its sale to OPKO Health, Inc. (NASDAQ: OPK) […]
Tessera Therapeutics’ $300 Million Series C Financing
Goodwin advised Tessera Therapeutics on the deal. Tessera Therapeutics announced its Series C financing, which totaled over $300 million. Tessera is a biotechnology company pioneering a […]
Regeneron Pharmaceuticals’ Acquisition of Checkmate Pharmaceuticals
Wachtell, Lipton, Rosen & Katz advised Regeneron on the deal, while Goodwin represented Checkmate Pharmaceuticals. Fried Frank acted as counsel to Centerview Partners, financial advisor to […]
Sanofi’s Exclusive Collaboration with Seagen
Arnold & Porter advised Sanofi on the deal while Goodwin Procter represented Seagen. Sanofi announced its exclusive collaboration with Nasdaq-listed biotech Seagen Inc. to design, develop and […]
Blackstone Life Sciences’ €300 Million Financing Collaboration with Sanofi
Goodwin advised Blackstone Life Sciences on the deal. Blackstone Life Sciences announced its strategic, risk-sharing financing collaboration with Sanofi, in which Blackstone will provide Sanofi with up […]
Blueprint Medicines’ Strategic Collaboration with Proteovant Therapeutics
Goodwin advised Blueprint Medicines on the deal. Blueprint Medicines announced its strategic collaboration with Proteovant Therapeutics that will leverage Proteovant Therapeutics’ artificial intelligence-enhanced targeted protein degradation platform […]
Janssen Pharmaceuticals’ Acquisition of Anakuria Therapeutics
Goodwin Procter advised Navitor Pharmaceuticals on the deal. Privately held Navitor Pharmaceuticals, LLC (“Navitor”), announced that Janssen Pharmaceuticals, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies […]
Trinity Acquisition Holdings Limited’s Hong Kong Listing
Goodwin Procter advised Trinity Acquisition Holdings Limited on the deal. Trinity Acquisition is one of the first SPACs that has submitted a listing application to the […]
Gandeeva’s $40 Million Series A Funding
Goodwin advised Gandeeva on the deal. Gandeeva announced its Series A funding led by Lux Capital and Leaps by Bayer, with participation from Obvious Ventures, Amgen Ventures, […]
LRQA’s Acquisition of Interest in ELEVATE
Baker McKenzie advised EQT on the transaction while Goodwin represented ELEVATE. EQT executed the sale of its interest in ELEVATE, a leading provider of ESG and supply […]
Acadia Pharmaceuticals’ Collaboration Agreement with Stoke Therapeutics
Goodwin Procter advised Acadia Pharmaceutical on the deal while Wilson Sonsini represented Stoke Therapeutics. Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced its collaboration agreement with Stoke Therapeutics, Inc. […]